Epithelial ovarian cancer is one of the most fatal gynecological malignancies in adult women. As studies on protein N-glycosylation have extensively reported aberrant patterns in the ovarian cancer tumor microenvironment, obtaining spatial information will uncover tumor-specific N-glycan alterations in ovarian cancer development and progression. matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) is employed to investigate N-glycan distribution on formalin-fixed paraffin-embedded ovarian cancer tissue sections from early-and late-stage patients. Tumor-specific N-glycans are identified and structurally characterized by porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry (PGC-LC-ESI-MS/MS), and then assigned to high-resolution images obtained from MALDI-MSI. Spatial distribution of 14 N-glycans is obtained by MALDI-MSI and 42 N-glycans (including structural and compositional isomers) identified and structurally characterized by LC-MS. The spatial distribution of oligomannose, complex neutral, bisecting, and sialylated N-glycan families are localized to the tumor regions of late-stage ovarian cancer patients relative to early-stage patients. Potential N-glycan diagnostic markers that emerge include the oligomannose structure, (Hex) 6 + (Man) 3 (GlcNAc) 2 , and the complex neutral structure, (Hex) 2 (HexNAc) 2 (Deoxyhexose) 1 + (Man) 3 (GlcNAc) 2 . The distribution of these markers is evaluated using a tissue microarray of early-and late-stage patients.
Introduction
Epithelial ovarian cancer (EOC) affects an estimated 1600 Australian women each year, with over 1000 succumbing to this aggressive malignancy. [1] Ovarian cancer (OC) is asymptomatic, which results in the diagnosis of most patients with metastatic diagnostics, and achieving these involves using clinicopathological information (grade, stage, and/or treatment response) in conjunction with molecular-level information, such as "omics" data.
Genomics approaches can divide OC into two distinct groups. Group I contains low-grade serous, endometrioid, mucinous, and clear cell carcinomas, while group II contains high-grade serous and endometrioid tumors. [3] This classification strategy, while beneficial, has limitations, such as gene transcription levels not mirroring levels of protein translation [4] and can only predict potential sites of PTMs. [5] A complete molecular understanding of globally regulated pathways in OC requires a combination of multi-"omics" information. Proteomics has been widely applied to OC tissue samples. El Ayed et al. measured the spatial distribution of intact proteins and tryptic peptides across stage III and IV adenocarcinoma, borderline, and benign tumor tissue sections. [6] S100 proteins, cytoskeleton modifying proteins, and an oviductspecific glycoprotein (OGP, Mucin-9, a marker of normal oviductal epithelium), were all observed to be spatially localized to tumor regions. Mucin-9 was previously found to be a tubal differentiation marker, indicating early events of ovarian carcinogenesis. Analysis of the glycan component of glycoproteins requires specific preparation approaches, which is analyzed through the field of glycomics.
Glycomics is the study of sugars present in complex molecules, including proteins, in an organism. There are two main types of protein-linked glycosylation; N-and O-linked, which are attached to asparagine and serine/threonine residues, respectively. [7] In the tumor microenvironment, aberrant Nlinked glycosylation patterns are associated with tumor growth, cancer development, and metastasis. [8] Aberrant glycosylation provides molecular-level glycomic profiles of different disease states relative to healthy samples. [9] The N-glycome is typically studied by enzymatic release by PNGase F followed by reduction, clean-up, and analysis using porous graphitized carbon (PGC)liquid chromatography (LC) -electrospray ionization (ESI)tandem mass spectrometry (MS/MS).
Evaluation of OC patient tissue offers the ability to directly correlate glycan changes with classified low-and high-grade OC. Samples can be preserved as fresh frozen (FF) or formalin-fixed paraffin-embedded (FFPE). Most studies use formalin fixation to avoid specific handling/storage requirements and expenses associated with storage and transport of fresh frozen samples. There have been only a handful of publications that study the glycomes of OC tissue. In 2015, Allam et al. isolated N-glycans from FF endometrioid, serous, and healthy OC tissue sections [10] and discovered that bisecting N-glycan structures were elevated in the serous OC tissue as well as the glycosyltransferase enzyme, MGAT 3. More recently, the glycomes from cancer tissue originating from the ovaries and peritoneum were compared using PGC-LC-ESI-MS/MS. [11] This study reported high levels of α-2-6 sialylated and bisecting N-glycan structures from both cancers originating from the ovaries and peritoneum. Several glycan structures specific to the cancer originating from the ovaries, such as LacdiNAc-type (GalNAcβ1-4GlNAc) motifs, were correlated with gene expression of B4GALNT3 and B4GALNT4. In 2017, Chen et al. used matrix-assisted laser desorption/ionization (MALDI)-MS to compare N-glycan profiles of different patho-
Significance Statement
Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) is a well-established technique used to spatially map biomolecules across fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue sections. However, this study presented a novel use for MALDI-MSI whereby N-glycans were spatially mapped across early-and late-stage FFPE ovarian cancer tissue sections with the aim to identify specific N-glycan structures that can differentiate between early-and late-stage patients. Furthermore, the construction of a tissue microarray (TMA) was also a novel aspect of this study whereby the initial results were validated using a larger patient cohort. It was discovered that multiple oligomannose structures, bisecting structures, and sialylated structures were observed to be higher in abundance in late-stage patients compared with early-stage patients. These findings provide a better understanding of ovarian cancer disease progression.
logical grades of EOC tissue and healthy controls. [12] A total of 80 N-glycan compositions were detected, with oligomannose Nglycans highly expressed in cancer relative to healthy. Four oligomannose and three fucosylated neutral complex N-glycans were combined together and analyzed by ROC using binary logistic regression rule to generate good discrimination. Overall, these publications concluded that there are N-glycan families specific to OC. However, it is unclear if tumor regions were isolated from underlying stroma or adipose, for instance, by laser capture microdissection (LCM). [13] MALDI-mass spectrometry imaging (MALDI-MSI) is a spatial technique applied to tissue sections to measure the distribution of analytes, including N-glycans. The recent complementation of N-glycan MALDI-MSI and PGC-LC-ESI-MS/MS as a workflow for comprehensive N-glycan analysis was first employed in 2015 as a proof of principle. [14] This straightforward method utilized FFPE murine kidney, therefore identifying confirmed N-glycan structures that could distinguish between the cortex, medulla, and pelvis. We have recently published a detailed protocol paper that provides readers with step-by-step instructions on combining MALDI-MSI with PGC-LC-ESI-MS/MS in order to obtain both spatial and structural information on protein-linked Nglycans, respectively. [15] In a proof of concept study, we have analyzed the N-glycan distribution on late-stage FFPE OC tissue (n = 3). [16] We identified 40 individual N-glycan structural and compositional isomers by PGC-LC-ESI-MS/MS and could discriminate between tumor, stroma, adipose, and necrotic regions of the ovarian tissue based on specific N-glycan families. Oligomannose N-glycans were predominantly expressed in tumor regions while complex N-glycans were the abundant protein-linked structure in the adjacent stroma. Here, we extend on this work to investigate whether N-glycans released from proteins in OC FFPE tissue sections could discriminate between early-and late-stage OC. The combination of spatial and structural information of the N-glycans offers the potential to discover specific N-glycans that are indicative of OC progression and lead to the development of targeted therapeutic strategies for OC patients. 
Experimental Section

Reagents
See Table 1 from our previous publications for a comprehensive list of chemicals, consumables, and equipment used in this protocol. [15, 17] 
FFPE Tissue Block and TMA Construction
Serous OC tissue from was obtained from patients during surgery from 2008 to 2017 at the Royal Adelaide Hospital with approval by the local ethics committee (RAH protocol number: 140101). The tissues were fixed as previously described. [14] A Leica EG 114OH embedder (Leica Biosystems) was used to create paraffin-embedded tissue blocks of early-stage (n = 3) and late-stage (n = 3) OC patients (Table S1 , Supporting Information). A tissue microarray (TMA) was manually constructed from six stage I and seven stage III FFPE tissue blocks, using the Chemicon Advanced Tissue Arrayer ATA100 (Table S2, Supporting Information). FFPE egg white was used as a positive PNGase F digestion control in the experiment.
Tissue Sectioning
Sectioning was performed as previously described. [15] Briefly, FFPE blocks were sectioned (6 µm thick) on either a Microm HM325 microtome (Zeiss, Göttingen, Germany) or Leica RM2255 Rotary microtome (Nussloch, Germany) and water bath mounted (39°C) onto ITO slides (Bruker Daltonics) or PEN membrane slides (MicroDissect). Slides were left to dry at 37°C for 1 h before storage.
N-Glycan MALDI-MSI of FFPE Tissue
Tissue Antigen Retrieval
Tissue sections were rehydrated using a standard procedure for citric acid antigen retrieval (CAAR). [15] Briefly, the tissue sections were heated at 60°C for 1 h over on a heatblock; washed in 100% v/v xylene, 100% v/v ethanol, 10 mm NH 4 HCO 3 (2 × 5 min), followed by a 10 min incubation in boiling 10 mm citric acid (pH 6.0) and then by heated at 98°C for 30 min on a heating block. Finally, tissue sections were immersed twice in 10 mm NH 4 HCO 3 and dried at room temperature in a humid chamber.
In Situ PNGase F Digestion and Matrix Deposition for Single Tissue Sections
PNGase F enzyme (40 µL) was spotted onto a nitrocellulose membrane and drop dialyzed against water for 2 h at room temperature. NH 4 HCO 3 (25 mm, pH 8.2) was added to the dialyzed PN-Gase F to a total volume of 200 µL and the PNGase F was printed onto tissue sections using a previously published protocol on the ChIP-1000 (Shimadzu, Japan). [15] ITO slides were marked at the edges with water-based white out and tissue sections are scanned at 2400 dpi on a CanoScan 5600 F (Canon) scanner for instrument teaching purposes. 2,5-DHB (20 mg mL −1 ) in 0.1% v/v TFA and 1 mm NaCl was sprayed onto prepared tissues using an optimized method on the HTX TM sprayer.
In Situ PNGase F Digestion and Matrix Deposition for TMA
PNGase F (40 µL) was added to NH 4 
MALDI-TOF/TOF Mass Spectrometry for Single Tissue Sections
MS data was acquired using an ultrafleXtreme MALDI-TOF/TOF mass spectrometer (Bruker Daltonics) controlled by flexControl (v3.4, Bruker Daltonics) and flexImaging (v4.0, Bruker Daltonics) in reflectron positive ion mode. Instrument-specific settings that were used are accessible via our previously published protocol paper. [15] 
MALDI-TOF/TOF Mass Spectrometry for TMA
MS data was acquired using an ultrafleXtreme MALDI-TOF/TOF mass spectrometer (Bruker Daltonics) controlled by flexControl (v3.4, Bruker Daltonics) and flexImaging (v4.0, Bruker Daltonics) in reflectron positive ion mode. Instrument-specific settings were as follows: 800-4500 m/z range, 700 Da matrix suppression, 2 kHz laser repetition rate, and 5 GS s −1 . Method-specific settings were as follows: 60% laser power and 2698 V detector gain. A total of 2000 shots were acquired at each position using the Smartbeam 3 medium laser diameter within a 100 µm raster width. N-glycan delocalization was assessed by acquiring spectra off-tissue. The MALDI-TOF/TOF instrument was externally calibrated using a quadratic fit prior to acquisition using the peptide calibration standard spots prior to MALDI-MSI.
Histological Staining
Following MALDI-MSI, matrix was eluted using 70% EtOH and sections were hematoxylin and eosin (H&E) stained as described previously. [15] Tumor regions on tissue sections were annotated by a histopathologist.
Data Analysis
MALDI-MSI data was analyzed by SCiLS Lab (version 2016b, SCiLS, Bruker Daltonics). Raw data was loaded and preprocessed by baseline subtraction and normalization to total ion count (TIC). Aligned peaks from the pre-processed data was used to generate log ion intensity maps to investigate spatial distribution of selected peaks. These log ion intensity maps were weakly denoised with automatic hotspot removal. To achieve a comprehensive identification and characterization of these structures, the following tools and methods were used: 1) Gly-coMod (http://web.expasy.org/glycomod/), which calculates the theoretical monosaccharide composition based on the parent mass obtained from LC-MS, and then links to the UniCarbKB database, [18] which lists known N-glycan structures from the literature, [19] 2) negative mode diagnostic fragmentation ions which match previously reported N-glycan structures, [20] and 3) the knowledge of N-glycosylation synthesis pathways.
PGC-LC-ESI-Ion Trap MS and MS/MS of N-Glycans Released from Laser Captured Microdissected FFPE Tissue Sections
In-Solution PNGase F Digestion
Tissue on PEN membrane slides (n = 6) were processed as described previously, with modifications. [15] Briefly, following a 5 min 60°C heating block incubation, 90 s xylene wash and 60 s EtOH wash, the tissue sections were stained with hematoxylin and a 604 259 µm 2 tumor region was selected and isolated by LCM from each section (using a Leica AS LCM microscope), and deposited into a micro-vial. The tissue was incubated (2 × 5 min) in 10 mm NH 4 HCO 3 . Solution was removed and replaced with 10 mm citric acid (pH 6) and heated at 98°C for 45 min. The tissue regions were washed twice with 10 mm NH 4 HCO 3 . Glycerol free PNGase F (2 µL, non-dialysed) was added to the FFPE tissue in a 10 µL total reaction volume (with 25 mm NH 4 HCO 3 ) for the tumor regions. The tissue digests were left overnight for approximately 16 h at 37°C.
N-Linked Glycan Release and Glycan Purification
The released N-linked glycans were reduced and desalted according to previously described methods. [15] Briefly, after acidification with 100 mm NH 4 COOH pH 5 (10 µL) for 60 min at room temperature, samples were dried in a vacuum centrifuge and reduced with 20 µL of 1 m NaBH 4 in 50 mm NaOH at 50°C for 3 h. The reduction was quenched with 2 µL glacial acetic acid and desalted using cation-exchange columns comprising 30 µL AG50W-X8 cation-exchange resin (BioRad, Hercules) pipetted on top of a C18 StageTip (Millipore). Residual borate was removed by the addition of methanol (× 3) and drying under vacuum. The glycans were further purified by tips using PGC slurry (GlycoClean H Cartridges, Prozyme) manually pipetted onto C18 StageTip (Millipore) as previously described. [15, 21] 
PGC-LC-ESI-Ion Trap MS and MS/MS
The released reduced N-glycans were resuspended in 10 µL of ultra-pure water and subjected to PGC-LC-ESI-MS/MS on a 1100 capillary and nano-pump LC system (Agilent Technologies, CA) coupled to amaZon ETD Ion Trap MS (Bruker Daltonics, Bremen, Germany) via a CaptiveSpray nano ionization source with nanoBooster (Bruker Daltonics) under the control of HyStar software (version 3.0.394.0, Bruker Daltonics) and Trap-Control (version 7.2, Bruker Daltonics). One microliter of reduced glycans was loaded onto a trapping column (Hypercarb, 30 × 0.32 mm, 5 µm particle size, Thermo Scientific) at a flow rate of 8 µL min −1 in 10 min using buffer A (ultra-pure water). Glycan separation was performed on a Hypercarb analytical column (100 × 0.075 mm, 3 µm particle size, Thermo Scientific) using water as buffer A and 60% v/v ACN as buffer B, at 800 µL min −1 flow rate using a linear gradient of 3-15.8% buffer B for 1 min, 15.8-40.3% buffer B for 49 min before washing in 60% buffer B for 10 min and a 15 min column equilibration in 3% buffer B. A total of 85 min chromatographic time was performed. The amaZon ETD ion trap MS was operated in negative mode with CaptiveSpray capillary voltage set to 1200 V in the mass range of m/z 300-1800. Scan mode of ultrascan with ICC target of 40 000 in 200 ms maximum accumulation time averaging 5 spectra and rolling average of 2 were set. Top three precursors were subjected to data-dependent acquisition where an ion threshold of 25 000 with −2 as preferred charge stage in the scanning range of m/z 100-2500. Exclusion was activated to exclude precursor after one spectrum and release after 0.2 min for CID fragmentation using enhanced smart fragmentation of 32 ms fragmentation time and 27% default collision energy at an amplitude of 70%. Raw data was analyzed using Data Analysis (version 4.0, Bruker Daltonics) and GlycoWorkbench (version 2.1). N-glycans identified and confirmed by PGC-LC-ESI-MS/MS were matched to the corresponding m/z values from MALDI-MSI as detailed previously. [15] 3. Results
Single Tissue Section Analysis from Early-and Late-Stage OC Patients
N-glycan MALDI MSI was performed on FFPE serous OC from early-(n = 3) and late-stage (n = 3) patients (Table S1 , Supporting Information), as previously described. [15] Spectra from the earlystage patients were summed and compared to late-stage patients.
To identify putative N-glycan structures from PNGase F treated regions, we compared the summed spectra from treated and nontreated regions to generate unique m/z values. Fourteen unique m/z values specific to PNGase F treated regions were identified (Figure 1) . To confirm that these m/z values were N-glycan structures, detailed structural information was obtained by PGC-LC-ESI-MS/MS analysis of N-glycans released from LCM tumor regions from hematoxylin stained consecutive tissue sections of early-and late-stage serous OC patients. Forty-two N-glycan structures (including structural and compositional isomers) were identified and characterized from the laser microdissected tumor-specific regions using PGC-LC-ESI-MS/MS analysis ( Table 1 ). This list was used to assign glycan structures to the 14 m/z values obtained by MALDI-MSI. Glycans were categorized into oligomannose, complex neutral, bisecting, and sialylated N-glycan families ( Table 1 ). Interestingly, hybrid N-glycan structures were only detected by PGC-LC-ESI-MS/MS analysis and were not associated to observed m/z values from MALDI-MSI.
The early-and late-stage serous OC summed spectra were annotated using the N-glycan structures identified and characterized by PGC-LC-ESI-MS/MS analysis (Figure 1 ). Overall, ion intensity maps show oligomannose N-glycans (Figure 2 and Figures S2-S5, Supporting Information) were observed to be more abundant in the summed MALDI-MSI spectra N-glycans released from late-stage relative to early-stage patients. Several complex neutral N-glycan structures, such as m/z 1809.639 (Hex) 2 (HexNAc) 2 (Deoxyhexose) 1 + (Man) 3 (GlcNAc) 2 , were observed only in the late-stage patients (Figure 3) . Specific bisecting (see Figures S9-S10, Supporting Information) and sialylated (Figures S11 and S12, Supporting Information) N-glycan structures followed a similar trend with m/z 2012.718 (Hex) 2 (HexNAc) 3 (Deoxyhexose) 1 + (Man) 3 (GlcNAc) 2 and m/z 1977.666 (Hex) 2 (HexNAc) 2 (NeuAc) 1 + (Man) 3 (GlcNAc) 2 being detected at low intensity or absent from the early-stage sum spectrum. Figure 2 and Figures S2-S5 , Supporting Information show that all oligomannose N-glycans were predominantly observed in tumor regions of the late-stage patients. m/z 1905.633 (Hex) 6 + (Man) 3 (GlcNAc) 2 is one example of an oligomannose to be abundantly observed in tumor regions of late-stage patients (see Figure 2a -f). Figure 2g shows the N-glycan structure assigned to the ion intensity maps in panels a-f based on the corresponding extracted ion chromatogram (panel h) and fragmentation (panel i). Furthermore, complex neutral N-glycans (Figure 3 and Figures S6-S8 , Supporting Information) were more intense in tumor regions of late-stage patients compared to early-stage patients, as well as being intense in the adjacent stroma regions. However, fucosylated, truncated biantennary neutral N-glycan, m/z 1485.533 (HexNAc) 2 (Deoxyhexose) 1 + (Man) 3 (GlcNAc) 2 was not consistent with this observation as it was only observed in necrotic regions, which is consistent with the literature (Figure S7 , Supporting Information). [16] The larger m/z 1809.639 (Hex) 2 (HexNAc) 2 (Deoxyhexose) 1 + (Man) 3 (GlcNAc) 2 was an example of a complex neutral N-glycan that is predominantly in tumor regions of late-stage patients (Figure 3a-f ). This N-glycan was structurally characterized by PGC-LC-ESI-MS/MS analysis, therefore confirming its structural and compositional features (panel i). 
TMA Analysis of Early and Late-Stage OC Patients
Tissue cores from sic stage I (4 × IA and 2 × IC) and seven stage III (6 × IIIC and 1 × IIIA) FFPE tissue blocks were constructed into an array and MALDI MSI was performed. Egg white cores were used as a PNGase F digestion control. Of the 14 previously observed N-glycan signals using single tissue sections, 12 were observed across the TMA cores (Table  S3 , Supporting Information). The two not observed were the sialylated (Figures S12 and S13, Supporting Information) Nglycan structures, which is likely due to the use of an HCCA as a matrix in conjunction with reflectron mode analysis for MALDI-MSI, which is known to result in sialic acid loss through metastable ion decay. ROC curves evaluated the ability of the 12 signals to differentiate between early-and late-stage tissue cores ( Table 2) . Certain glycans, such as m/z 1809.6, annotated as (Hex) 2 (HexNAc) 2 (Deoxyhexose) 1 + (Man) 3 (GlcNAc) 2 , and 1647.6, annotated as (Hex) 1 (HexNAc) 2 (Deoxyhexose) 1 + (Man) 3 (GlcNAc) 2 , were more prominent in late-stage tumor cores. One core from an early-stage patient (T4, stage IC), however, showed higher intensity signals for these N-glycans com-pared to the other early-stage cores. Table 2 shows the effect on the obtained the area under the curve (AUC) values after ROC assessment with and without T4.
Discussion
We applied our established N-glycan MALDI-MSI and PGC-LC-ESI-MSMS workflow to FFPE serous OC tissue and confirmed notable N-glycan differences between early-and late-stage patients. These alterations have previously been observed as a result of changes to the N-glycosylation pathway in cancer as reflected by expression of different glycotransferase genes and glycan structures. [10, 16, 22] Oligomannose N-glycans have consistently been found to be highly abundant on membrane glycoproteins from OC cell lines [22] and from stage IIIC serous OC. [16] This is the first time that the spatial protein glycosylation of late-stage OC patients has been compared to early-stage patients using this approach. The study confirmed oligomannose Nglycan structures predominantly in late-stage tumor regions (see Figure 2 and Figures S2-S5 , Supporting Information). Murine and human pluripotent stem cells have presented increased oligomannose N-glycans, therefore indicating cancer stem cell populations could present a similar glycosylation pattern. [23, 24] Man9 structures have been also found in mouse breast tumor models and human sera of patients with breast cancer. [25] Complex neutral and fucosylated N-glycan structures were localized to late-stage tumor regions and were more intense in adjacent stroma regions than in the tumor, as previously detailed. [16] MALDI-MSI analysis determined (HexNAc) 2 (Deoxyhexose) 1 + (Man) 3 (GlcNAc) 2 was spatially distributed across a mixture of early-and late-stage patients, which is not consistent with the other complex neutral and fucosylated N-glycan structures only seen in the late-stage patients ( Figure S7 , Supporting Information). Upon further investigation, the pathologist no-ticed that this early-stage patient, shown in panel c of all figures, contains necrotic and tumor regions. Therefore, the observation of (HexNAc) 2 (Deoxyhexose) 1 + (Man) 3 (GlcNAc) 2 in this patient is consistent with previous data that concludes this specific Nglycan structure is localized to necrotic regions. [16] Other complex neutral N-glycan structures, (Hex) 2 (HexNAc) 2 (Deoxyhexose) 1 + (Man) 3 (GlcNAc) 2 and (Hex) 2 (HexNAc) 2 + (Man) 3 (GlcNAc) 2 , were observed to be highly intense in both tumor and stroma regions of late-stage tissues (Figure 3 and Figure S9 , Supporting Information, respectively). These structures were confirmed by PGC-LC-ESI-MS/MS, but, to the contrary, these complex neutral and fucosylated N-glycans were found in cell lines to be more intense in healthy cells compared to tumor cells. [22] This may suggest that OC cell lines do not present identical N-glycomes to OC tissue. In serous and endometrioid OC tissues, it has been discovered that core fucosylation is elevated. [24, 26, 27] This observation is consistent with the results presented herein.
Bisecting N-glycan structures have been extensively observed in serous OC cell lines and tumor regions of serous OC tissue. [10, 22] This observation is consistent with the MALDI-MSI analysis reported here, where two galactosylated bisecting structures were detected predominantly in tumor regions of late-relative to early-stage patients ( Figure S11 , Supporting Information). However, the agalactosylated bisecting N-glycan structure, (HexNAc) 3 (Deoxyhexose) 1 + (Man) 3 (GlcNAc) 2 , was not consistent with the galactosylated structures ( Figure S10 , Supporting Information). This observation is novel and requires further investigation into specific glycosyltransferase activities surrounding early-and late-stage patients. Recently, bisecting N-glycan structures have been found to be associated with OC cell survival by correlation with MGAT 3 expression (Nacetylglucosaminyltransferase III, GnT-III), which synthesizes bisecting GlcNAc by adding GlcNAc in a β1-4 linkage to the core N-glycan. [28] However, in breast cancer tissue, the levels of the GnT-III enzyme are low compared to OC studies. For example, breast cancer tissues have lower levels of GnT-III relative to normal breast tissue [29] while OC tissues have higher levels of GnT-III relative to normal ovarian and fallopian tube tissues. [24, 26] The expression of GnT-III in OC cell lines is believed to be regulated by epigenetic hypomethylation. [22] Additionally, GnT-III mRNA levels and enzymatic activity were seen to be increased in ovarian tumor tissues derived from mouse models and human samples of endometrioid ovarian carcinoma. [9] Sialylated N-glycan structures have previously been found to be glyco-markers of tumorigenesis. [11, 22] (Hex) 2 (HexNAc) 2 (NeuAc) 1 + (Man) 3 (GlcNAc) 2 was discovered in our study to be predominantly in late-stage OC relative to the earlystage patients ( Figure S12 , Supporting Information). However, PGC-LC-ESI-MS/MS chromatography and fragmentation was unable to elucidate different isomeric sialylated structures, such as α-2,3 and α-2,6 sialic acid linkage. It has been shown that the α-2,6 linkage of sialic acid is increased in OC cell lines relative to normal cell lines while α-2,3 linkage is increased in normal cell lines relative to OC cell lines. [22] MALDI-MSI of a TMA consisting 6 early-and 7 late-stage OC tissue section cores revealed 12 of the 14 unique m/z values observed. These signals corresponded to oligomannose, complex neutral, and bisecting N-glycans (Table S3 , Supporting Information). After annotation, two (T1 and T2, from serous OC, stage IC tissue) of the six early-stage cores were removed from assessment as they showed little to no sign of tumor regions (Table 2 and Table S2 , Supporting Information). ROC assessment using the remaining four early-stage cores compared with the annotated tumor regions of seven late-stage cores highlighted particular signals, m/z 1809.6 and m/z 1647.6, to be more prominent in late-stage patients compared with early-stage patients. Early-stage T4 (stage IC) showed higher intensity signals seen in late-stage cores, and the effect of this patient core on obtained AUC values from ROC assessment is highlighted in Table 2 . For 1647.6 and 1809.6, AUCs increased from 0.559 to 0.768 and 0.654 to 0.786, respectively, when T4 is removed from assessment. T4, which is a serous papillary carcinoma of the ovary of stage IC, could be a misdiagnosed stage IIIA where the metastatic site was not discovered. Stage IIIA is defined as cancer cells in the lining of the abdomen cavity and this can only been seen under the microscope and can be missed. This preliminary assessment provides a strong justification for a larger TMA cohort N-glycan assessment to assess the ability of these N-glycans to stratify early-and late-stage patients. The signals not observed corresponded to sialylated structures observed in the whole tissue section analysis. The absence of sialylated structures in the TMA is likely due to the combination of HCCA matrix coupled with reflectron mode analysis. In this study, it was not expected to see many sialylated species, since we heated the sample during antigen retrieval and used reflectron mode, known to desialylate glycan structures. To address this caveat in future involves optimizing a method for linear and/or negative mode and/or the use of chemical modifications to derivatize the sialylated species such that they are not cleaved in MALDI-MSI. Holst et al., developed a novel derivatization method where in situ di-methylamidation is performed to identify linkage-specific sialylated N-glycans using MALDI-MSI. [30] In that study of FFPE colon carcinoma tissue, sialylated N-glycans were discovered to be α-2-3 linkage in stroma, tumor, and necrotic regions, while sialylated N-glycans with α-2-6 linkage were observed in necrotic, collagen-rich, and red blood cell regions. However, the limitation with this novel derivatization method is that other N-glycan isomeric structures were not considered (i.e., oligomannose, complex/hybrid).
Concluding Remarks
In summary, this is the first study where early-and late-stage serous OC patient tissues have been compared by MALDI-MSI to spatially map protein N-glycans using PGC-LC-ESI-MS/MS to structurally characterize the N-glycan masses. A total of 14 N-glycans were confirmed from MALDI-MSI across tumor and non-tumor regions, while 42 N-glycan structures (including structural and compositional isomers) were identified and characterized using PGC-LC-ESI-MS/MS. The spatial distribution and localization of specific N-glycans were visualized in the tumor regions of late-stage relative to early-stage serous OCs. N-glycans of interest that classified these late-stage patients by their abundance included the oligomannose structure, (Hex) 6 + (Man) 3 (GlcNAc) 2 , and the complex neutral structure, (Hex) 2 (HexNAc) 2 (Deoxyhexose) 1 + (Man) 3 (GlcNAc) 2 . However, further investigations are required to further validate these observations using a larger TMA patient cohort as well as to determine the function and significance of stage-specific glycans for OC progression.
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